Obesity does not impact perioperative outcomes in women undergoing robotic hysterectomy, according to a recent study.
Obesity does not impact perioperative outcomes in women undergoing robotic hysterectomy, according to a study presented at the Society of Laparoscopic Surgeons’ Minimally Invasive Surgery Week.
Karina Hew, MD, et al, conducted a single-center, retrospective study of 274 patients who underwent robot-assisted hysterectomy for both benign and malignant indications. Data collected included age, body mass index (BMI), race, medical comorbidities, previous abdominal surgeries, pathology and uterine weight. Perioperative outcome variables included surgical times, intraoperative and post-operative complications, estimated blood loss (EBL), length of stay and hospital charges.
Of the patients, 51.8% (p=142) were obese and 48.2% (p=132) were not obese, as defined by the World Health Organization’s 2004 BMI classification table. Demographic data, number of previous abdominal surgeries, type of pathology and number of cancer cases were similar between two groups.
Outcomes were similar in both the obese and non-obese groups:
• EBL: 11 9ml vs 109 ml (p=.41)
• Total surgical length in minutes: 141 vs 133 (p=.15)
• Console time in minutes: 39 vs 42 (p=.38)
• Length of stay in days: 1.78 vs 1.64 (p=.63)
• Post operative complications: 11.4% vs 15.2% (p=.16)
• Total hospital cost: $10,950.00 vs $9,638.00 (p= 0.18)
Unlocking placenta accreta spectrum with single-cell gene targets
April 18th 2024Discover how cutting-edge single-cell RNA sequencing unveils molecular insights into placenta accreta spectrum disorders, potentially revolutionizing diagnostics and treatments for this life-threatening pregnancy complication.
Read More
Excessive gonadotropins in IVF: Effects on mosaicism and live birth
April 12th 2024A recent study revealed a correlation between high doses and prolonged duration of exogenous gonadotropin use during in vitro fertilization and increased embryonic mosaicism alongside diminished live birth rates, prompting reconsideration of dosage and duration protocols.
Read More